Aclaris Therapeutics, Inc. — Director's Dealing 2026

Feb 6, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aclaris Therapeutics, Inc. (ACRS)
CIK: 0001557746
Period of Report: 2026-02-02

Reporting Person: Balthaser Kevin (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-02-02	Restricted Stock Units	$	A	99100	Acquired		Common Stock (99100)	Direct
2026-02-02	Employee Stock Option (Right to Buy)	$3.61	A	346800	Acquired	2036-02-01	Common Stock (346800)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F2: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

F3: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.